Resources from the same session
Emerging data on the role of ADCs in the clinical care pathways for advanced NSCLC patients
Presenter: Pasi Jänne
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Slides
Webcast
Improving the safety profiles of ADCs: Early detection and optimal management of toxicities
Presenter: Maurice Pérol
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Slides
Webcast
Antibody-drug conjugates: Novel combinations with precision therapeutics and the quest for biomarkers
Presenter: Anne-Marie Dingemans
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Webcast
Concluding remarks
Presenter: Pasi Jänne
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Webcast